Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 447.50
Bid: 440.00
Ask: 455.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.409%)
Open: 447.50
High: 447.50
Low: 447.50
Prev. Close: 447.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AGM Statement

19 Dec 2023 07:00

RNS Number : 1950X
Tristel PLC
19 December 2023
 

Tristel plc

("Tristel", the "Company", or the "Group")

AGM Statement, notice of results and planned CEO succession

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, will hold its Annual General Meeting at 11am today at the offices of Cavendish, One Bartholomew Close, London EC1A 7BL.

 

Paul Swinney, Chief Executive Officer, will address the meeting with the following update:

 

"I am pleased to report that the Company has had a record first half with revenue for the six months ending 31 December 2023 expected to be £20.7m, an increase of 18% compared to £17.5m in the first half of last year. Revenue growth has been delivered across all our geographical markets. Gross margin remains above 80% in line with our expectations.

 

"In the United States, Parker Laboratories, our manufacturing and distribution partner, completed its first production run for Tristel ULT in early October, following receipt of our FDA approval in June 2023. This has enabled Parker to stock its national distribution network and provide product to the first beta site users. We expect to make steady progress in building our customer base throughout the United States during the second half of our financial year. We remain very excited about our prospects as we begin serving the largest healthcare market in the world.

 

"The business is performing strongly on all fronts and the confidence that we expressed in October in our medium-term outlook remains unchanged. With the growth possibilities for our business stronger than ever, and as a business with no debt and forecast cash balances of approximately £10.4m after payment of this year's final dividend on 22 December, we are in a strong position to capitalise upon our global leadership position in the medical device decontamination market." 

 

Notice of Results

The Company's unaudited interim results will be announced on 26 February 2024.

 

CEO succession planning

In addition, Paul Swinney, co-founder of the business in 1993 and Group CEO for the past thirty years, has informed the Board of his intention to retire within the next twelve months. Paul will continue in his post until a successor is appointed and has committed to remain available thereafter to support and advise the business in executing a successful transition in the leadership of the Group. The Board has, therefore, initiated a formal succession process, supported by the global organisational consulting firm The Coulter Partnership, that will consider both external and internal candidates.

 

The Group's new CEO will join a strong executive leadership team with significant functional and market experience, gained from within and outside the business.

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Chief Financial Officer

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Charlotte Edgar

Mob: 07884 664 686

Alice Woodings

Mob: 07407 804 654

Cavendish Capital Markets Limited

Tel: 020 7220 0500

Geoff Nash/Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation ("MAR") EU no.596/2014. Upon the publication of this announcement via Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMEVLFFXLLXFBL
Date   Source Headline
4th Nov 20112:10 pmRNSDirector/PDMR Shareholding
24th Oct 20119:51 amRNSDirector/PDMR Shareholding
24th Oct 20117:01 amRNSDirectorate Change
24th Oct 20117:00 amRNSFinal Results
7th Sep 20117:00 amRNSFull regulatory approval for Fuse and Jet in China
9th Aug 20118:37 amRNSDirector's Shareholding
8th Aug 20117:00 amRNSCash inflow regarding R&D spend
25th Jul 20117:00 amRNSTrading update & notice of results
6th Jun 20117:00 amRNSApproval for Wipes System from VAH in Germany
12th May 20118:00 amRNSChina Licence received
6th May 20117:00 amRNSDirector Dealing
4th May 20112:38 pmRNSDirector Dealing
4th May 20117:00 amRNSDirector/PDMR Shareholding
28th Apr 20112:08 pmRNSTrading Update
14th Mar 20117:00 amRNSHalf Yearly Report
31st Jan 20117:00 amRNSCompletion of Clean Room & Notice of Results
30th Dec 20107:00 amRNSTermination of Agreement with Clorox
14th Dec 201011:15 amRNSResult of AGM
22nd Nov 201010:12 amRNSResult of General Meeting
12th Nov 201010:55 amRNSDirector/PDMR Shareholding
8th Nov 20103:06 pmRNSDirector Shareholding
5th Nov 201011:32 amRNSPlacing to raise £3.9million
18th Oct 20107:00 amRNSFinal Results
9th Sep 20107:00 amRNSTrading Statement
1st Jul 20107:00 amRNSDirector/PDMR Shareholding
28th Jun 201010:52 amRNSDirector/PDMR Shareholding
8th Jun 20104:01 pmRNSDirector/PDMR Shareholding
7th Jun 20105:15 pmRNSDirector/PDMR Shareholding
2nd Jun 20103:23 pmRNSDirector/PDMR Shareholding
2nd Jun 20107:00 amRNSDirectorate Change
19th Mar 20107:00 amRNSDirector/PDMR Shareholding
8th Mar 20107:00 amRNSHalf Yearly Report
25th Feb 20107:00 amRNSChange of Adviser
15th Dec 200912:03 pmRNSAGM Statement
4th Dec 20097:00 amRNSDirector/PDMR Shareholding
25th Nov 200910:35 amRNSGeneral Meeting
9th Nov 20097:00 amRNSPlacing and Notice of General Meeting
28th Oct 20099:14 amRNSDividend
13th Oct 20098:35 amRNSGrant of options
12th Oct 20097:00 amRNSFinal Results
18th Sep 20097:00 amRNSLicensing agreement
3rd Jul 200911:28 amRNSDirectors' Dealing
3rd Jul 20097:00 amRNSAcquisition and Placing
11th May 20097:00 amRNSExclusive UK distribution agreement
17th Mar 20099:35 amRNSCorrection to Record Date
16th Mar 20097:00 amRNSHalf Yearly Report
9th Mar 20097:00 amRNSNew infection control range for dental practices
8th Jan 20097:00 amRNSDirector/PDMR Shareholding
17th Dec 20087:00 amRNSAGM Statement
7th Nov 20087:00 amRNSNHS Supply Chain listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.